Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re

UTILITY PATENT APPLICATION

(Only for new nonprovisional applications under 37 CFR 1.53(b))

**TRANSMITTAL** 

spond to a confection of information diffess it displays a valid OMB control number.		
Attorney Docket No.	2260/119	်င္ကက ≡
First Inventor	Rok Grahek	. S. O.
Title	See 1 in Addendum	i 2986
Express Mail Label No.	EV 333083553 US	154

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450		
1.	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. CD-ROM or CD-R (2 copies); or  ii. Paper  c. Statements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1499 Citations 13. Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  Other: Unexecuted Declaration and Power of Attorney		
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:			
Continuation    Divisional   Continuation-in-part (CIP)   Of prior application No.:			
X Customer Number: 02101 OR Correspondence address below			
Name			
Address			
City	State Zip Code		
	elephone Fax		
Name (Print/Type) Barbara Carter Signature Sand Cart	Registration No. (Attorney/Agent) 33,198  Date 10/30/2003		

This collection of information is required by 37 (FR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rok Grahek, Dusan Milivojevic and Andrej Bastarda

Application No.: Not yet assigned

Group No.: Not yet assigned

Filed: Herewith

Examiner: Not yet assigned

For: Process for Obtaining HMG-CoA Reductase Inhibitors of High Purity

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **EXPRESS MAIL CERTIFICATE**

"Express Mail" label number EV 333083553 US Date of Deposit 10/30/2003

I hereby state that the following attached paper or fee

Utility patent application and related application parts

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above and is addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Barbara J. Carter

Signature of person mading paper or fee

## Addendum

1. Process for Obtaining HMG-CoA Reductase Inhibitors of High Purity